TrialSignal
Clinical trial intelligence report
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT04650451-Jul 28, 2026
NCT ID
NCT04650451
Status
SUSPENDED
Phase
Phase 1/2
Sponsor
Bellicum Pharmaceuticals
Executive brief
Investment-Ready Snapshot
Bellicum Pharmaceuticals is advancing BPX-603, a HER2-targeted dual-switch CAR-T cell therapy, aimed at treating advanced HER2-positive solid tumors. The market for HER2-targeted therapies is significant, particularly in breast and gastric cancers, where existing therapies may have limited efficacy in heavily pre-treated populations. The suspension of the trial due to dose-limiting toxicity in a related study raises concerns regarding safety and may impact investor confidence and future funding. However, if successful, BPX-603 could provide a novel treatment option in a competitive landscape dominated by established therapies such as trastuzumab and newer agents. The potential for a differentiated safety profile through the dual-switch mechanism may enhance its market positioning.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04650451
Indication
HER-2 Gene Amplification
Modality
cell therapy
Target
HER2 (Human Epidermal Growth Factor Receptor 2)
Intervention
chimeric antigen receptor (CAR) T cell therapy
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.